Our findings expand our understanding of the AURKA degradation pathway, and provides a new theoretical basis for the cancer therapy targeting AURKA, but more studies are needed on how TIALD directs its targeting to lysosomes by binding to AURKA. Here, AURKA is linked to cancer.